Should Aquestive Therapeutics Be Worried About This FDA Response?

Health and Healthcare

Published: September 28, 2020 10:14 am

Aquestive Therapeutics Inc. (NASDAQ: AQST) has announced that it had received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA). Usually, these letters spell disaster for firms in the biopharmaceutical industry, and Aquestive shares were crushed on Monday.

The FDA issues CRLs to indicate that the review cycle for an application is complete but the application cannot be approved in its current form. This CRL was in reference to Aquestive’s New Drug Application (NDA) for Libervant (diazepam) Buccal Film for the management of seizure clusters. In the CRL, the FDA cited that certain weight groups in the study showed a lower drug exposure level than desired.

The company intends to provide to the FDA additional information on pharmacokinetic modeling to demonstrate that dose adjustments will obtain the desired exposure levels. No other safety, clinical pharmacology/biopharmaceutics or Chemistry, Manufacturing and Controls issues were identified in the CRL.

The FDA did cite a small number of protocol deviations in blood draws in one of the studies in the NDA. Aquestive’s management believes, based on discussions with the FDA, that the company will not need to conduct any further clinical studies in order to cure the items cited in the CRL, and it will confirm that view in its upcoming follow-up meeting with the FDA.

Looking ahead, the firm believes that this CRL will not be a barrier to ultimate approval, as the CRL was limited to providing additional information on pharmacokinetic modeling for an adjusted dosing regimen for a limited subset of patient weight categories.

Aquestive stock traded down about 35% Monday morning to $4.92, in a 52-week range of $1.41 to $10.00. The consensus price target is $17.83.

24/7 Wall St.
5 Jefferies High-Conviction Health Care Stocks May Be Huge Q4 Winners

The Average American Has No Idea How Much Money You Can Make Today ^(Sponsor)

The last few years made people forget how much banks and CD’s can pay. Meanwhile, interest rates have spiked and many can afford to pay you much more, but most are keeping yields low and hoping you won’t notice.

But there is good news. To win qualified customers, some accounts are paying almost 10x the national average! That’s an incredible way to keep your money safe and earn more at the same time. Our top pick for high yield savings accounts includes other benefits as well. You can earn up to 3.80% with a Checking & Savings Account today Sign up and get up to $300 with direct deposit. No account fees. FDIC Insured.

Click here to see how much more you could be earning on your savings today. It takes just a few minutes to open an account to make your money work for you.

Our top pick for high yield savings accounts includes other benefits as well. You can earn up to 4.00% with a Checking & Savings Account from Sofi. Sign up and get up to $300 with direct deposit. No account fees. FDIC Insured.

¹https://www.fdic.gov/national-rates-and-rate-caps